NCT07044557 MeDex: No Perioperative Dexamethasone in Brain Metastases
| NCT ID | NCT07044557 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Louisville |
| Condition | Brain Metastases |
| Study Type | INTERVENTIONAL |
| Enrollment | 35 participants |
| Start Date | 2026-08-01 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 35 participants in total. It began in 2026-08-01 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).
Eligibility Criteria
Inclusion Criteria: 1. New brain tumor(s) on imaging 2. Visceral mass(es) suspicious or confirmed for neoplasm a. Patients with lung mass suspicious for primary lung cancer and no prior diagnosis must undergo biopsy of the lung mass prior to resection of brain metastasis(es) to exclude histology (i.e., small cell lung carcinoma) that would not benefit from resection 3. No contraindications for craniotomy 4. Age ≥ 18 years 5. ECOG performance status ≤ 2 (i.e., ambulatory \> 50% of waking hours) 6. Midline shift on MRI ≤ 10 mm 7. Craniotomy planned to resect \>75% of the enhancing mass (surgeon's judgment) Exclusion Criteria: 1. Presence of BMs not eligible for resection that are each \> 2 cm in any one dimension 2. \>4 BMs not eligible for resection that are each 2 cm in any one dimension 3. Treatment with laser interstitial thermal therapy (LITT) 4. High concern for primary CNS lymphoma 5. Diagnosis of small cell lung carcinoma 6. Any receipt of Dex 7. Steroid use in the past month 8. A condition that requires steroids 9. Stage 4 chronic kidney disease (GFR\<30) 10. Pregnant or breastfeeding
Contact & Investigator
Akshitkumar Mistry, MD
PRINCIPAL INVESTIGATOR
University of Louisville
Frequently Asked Questions
Who can join the NCT07044557 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07044557 currently recruiting?
Yes, NCT07044557 is actively recruiting participants. Contact the research team at akshitkumar.mistry@louisville.edu for enrollment information.
Where is the NCT07044557 trial being conducted?
This trial is being conducted at Louisville, United States.
Who is sponsoring the NCT07044557 clinical trial?
NCT07044557 is sponsored by University of Louisville. The principal investigator is Akshitkumar Mistry, MD at University of Louisville. The trial plans to enroll 35 participants.